Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tramadol; JNS013 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Tramadol Hydrochloride; JNS013 | DRUG | - |
Inclusion Criteria: * Patients with chronic pain due to OA of the knee or LBP that persists for more than 3 months at the initiation of the observation period * Patients who received oral NSAIDs at a usual highest dose for at least 14 consecutive days during 3 months before the initiation of the ob...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
Tramadol is being studied as a treatment for osteoarthritis, a musculoskeletal condition involving joint pain and degeneration. Johnson & Johnson developed it under the code JNS013, and a Phase 2 exploratory trial evaluated tramadol hydrochloride in patients with osteoarthritis of the knee or low back pain. It is an investigational use, not an approved osteoarthritis indication.
Johnson & Johnson, which trades under the ticker JNJ, is the developer associated with tramadol under the designation JNS013. The company sponsored the Phase 2 exploratory study of tramadol hydrochloride in osteoarthritis of the knee or low back pain. Tramadol itself is a widely available analgesic, but this specific osteoarthritis development program belongs to Johnson & Johnson.
Tramadol is in Phase 2 development for osteoarthritis. One Phase 2 exploratory trial has been completed, and no active trials are currently listed for this program. The completed study enrolled 119 patients and evaluated tramadol hydrochloride in osteoarthritis of the knee or low back pain. It remains an investigational use in this setting.
Tramadol has been studied in one completed Phase 2 trial, NCT00752661, titled An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain. The trial enrolled 119 participants aged 20 years and older, was uncontrolled, and was not randomized or double blinded. No active trials are listed for this program.
Yes, JNS013 is an alternative designation for tramadol, also known as tramadol hydrochloride. Johnson & Johnson developed the osteoarthritis program under the JNS013 code. Searches for either name refer to the same small molecule being evaluated in a completed Phase 2 trial for osteoarthritis of the knee or low back pain.